In multiple CF preclinical models, ELX-02 significantly rescued CFTR function with a ten times improvement in the therapeutic index over gentamicin and other aminoglycoside derivatives, and CFTR activity could be further augmented by the addition of the CFTR potentiator, corrector, or NMD inhibitor [64,65]. Here, CFTR is linked to cystic fibrosis.